ALLMedicine™ Prolactinoma Center
Research & Reviews 355 results
Journal of Medical Case Reports; Tng EL, Teo AE et. al.
Mar 18th, 2023 - Resistance to dopamine agonists is not uncommonly seen in prolactinomas. However, development of resistance to dopamine agonists after an initial period of robust treatment response is rare, and only 39 cases have been reported in the past four de...
Andrology Rudman Y, Duskin-Bitan H et. al.
Mar 11th, 2023 - Men harboring prolactinomas frequently suffer from central hypogonadism with secondary anemia. They present insidious and non-specific symptoms of hypogonadism, making it difficult to diagnose the disease and determine its duration. The result is ...
Clinical Neuropharmacology; Springer C, Rodgers R et. al.
Mar 7th, 2023 - Cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas. Here, we describe the case of a 32-year-old woman with a pituitary prolactinoma who was treated with cabergoline for 1 year, during which time sh...
Journal of Endocrinological Investigation; Wu N, Zhu D et. al.
Mar 1st, 2023 - Prolactinomas are one of the most common pituitary neuroendocrine tumors (PitNETs), accounting for approximately 50% of all pituitary tumors. Dopamine agonists are the main treatment for prolactinoma, but a small number of patients are still resis...
Endocrine Tang H, Cheng Y et. al.
Jan 24th, 2023 - The dopamine agonists (DA) have been used widely to treat prolactinomas. However, it is difficult to predict whether the patient will be responsive to DA treatment. We aimed to investigate whether the in vivo expression of DRD2 based on 18F-fallyp...
Guidelines 1 results
The Journal of Clinical Endocrinology and Metabolism; Freda PU, Beckers AM et. al.
Apr 9th, 2011 - The aim was to formulate practice guidelines for endocrine evaluation and treatment of pituitary incidentalomas. Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails and one in-per...
Clinicaltrials.gov 18 results
Nov 1st, 2022 - Prolactinoma is a pituitary adenoma caused by excessive prolactin secretion. More than 70% of patients are women. Many physiological conditions such as pregnancy, breastfeeding, breast stimulation, stress, exercise and sleep can also increase PRL ...
Mar 31st, 2022 - KRANIOPHARYNGEOM Registry 2019 will prospectively collect and descriptively analyse data on diagnostics, treatment, and follow-up of patients with craniopharyngioma. In continuation of preceding studies also patients with xanthogranuloma, meningio...
Sep 13th, 2021 - Type 1 diabetes (T1D) continues to be a disease plagued by hyperglycemia, insulin resistance (IR), and increased cardiovascular disease (CVD) despite advances in insulin delivery and glucose monitoring. Therefore new approaches are needed. Bromocr...
Sep 8th, 2021 - Recent epidemiological studies indicate that clinically relevant PiT have a prevalence around 1%. The Neuromed Scientific Institute for Research and Cure (IRCCS) is a third referral center for the diagnosis and treatment of patients with hypothala...
Jun 22nd, 2021 - This is a single-site validation study of a novel quality of life study for patients undergoing medical therapy for prolactinoma. Patients will be consented before starting their medical regimen and complete the "Prolac-10" questionnaire for basel...
News 13 results
May 25th, 2022 - Researchers published the study covered in this summary on medRxiv.org as a preprint that has not yet been peer reviewed. Key Takeaways Patients with hyperprolactinemia secondary to a newly diagnosed prolactinoma who received 6 months of treatment...
Oct 28th, 2020 - When there is an abnormality in the pituitary gland, many potential areas could be affected because of the extent and range of hormones produced by the “master gland,” Ashlyn Smith, PA-C, of Endocrinology Associates, Scottsdale, Ariz. , said in a p.
Clinical Endocrinology News;
Apr 26th, 2018 - What if the tumor grows in pregnancy? During pregnancy, high estrogen levels from the placenta can stimulate prolactinoma growth, and the dopamine agonist’s inhibitory effect is gone once that medication’s been stopped. This means that “We have bo.
Beth Gundy, PA-C, Laura M. Gunder-Mcclary, DHSC, MHE, PA-C
Feb 1st, 2012 - A 29-year-old woman with a history of frequent migraines presented to her primary care provider for a refill of medication. For the past two years she had been taking rizatriptan 10 mg, but with little relief.
Sonia Bahroo, PA-C
Nov 1st, 2011 - A 42-year-old obese woman with type 2 diabetes, diabetic retinopathy, hypertension, and hirsutism presents to discuss an elevated prolactin level of 144. 8 ng/mL (normal range, 4.